New blood pressure drug helps people with uncontrolled hypertension in trial [CNBC]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: CNBC
pregnant, during a prenatal appointment on Thursday, February 4, 2016 in San Francisco, Calif. A new type of medication may help lower blood pressure in people with , researchers reported Saturday at the annual meeting of American College of Cardiology in Chicago. In a pivotal Phase 2b clinical trial, patients who took the experimental medication lorundrostat along with two or three currently available hypertension drugs saw a decrease in (the upper number) that was 8 points greater than what was seen in patients who got a placebo. The study will be published in The New England Journal of Medicine. “This new potential therapy for hypertension is exciting,” said the study's lead author, Dr. Luke Laffin, co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic's Heart, Vascular and Thoracic Institute. “We do a poor job controlling blood pressure in the U.S.” According to the , nearly half of adults in the U.S. have hypertension; among them, less than 1 in 4
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.MarketBeat
- Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” RoundupGlobeNewswire
- A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
MLYS
Earnings
- 11/10/25 - Beat
MLYS
Sec Filings
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- MLYS's page on the SEC website